Article Text
Abstract
Sialorrhoea is a common and problematic symptom that arises from a range of neurological conditions associated with bulbar or facial muscle dysfunction. Drooling can significantly affect quality of life due to both physical complications such as oral chapping, and psychological complications such as embarrassment and social isolation. Thicker, tenacious oral and pharyngeal secretions may result from the drying management approach to sialorrhoea. The management of sialorrhoea in neurological diseases depends on the underlying pathology and severity of symptoms. Interventions include anticholinergic drugs, salivary gland-targeted radiotherapy, salivary gland botulinum toxin and surgical approaches. The management of thick secretions involves mainly conservative measures such as pineapple juice as a lytic agent, cough assist, saline nebulisers and suctioning or mucolytic drugs like carbocisteine. Despite a current lack of evidence and variable practice, management of sialorrhoea should form a part of the multidisciplinary approach needed for long-term neurological conditions.
Statistics from Altmetric.com
Linked Articles
- Editors' commentary
Other content recommended for you
- Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders
- Developing an intrasalivary gland botox service for patients receiving long-term non-invasive ventilation at home: a single-centre experience
- Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis
- Scoring hypoechogenic areas in one parotid and one submandibular gland increases feasibility of ultrasound in primary Sjögren’s syndrome
- Problems with botulinum toxin treatment in mitochondrial cytopathy: case report and review of the literature
- Management of drooling in children
- Bilateral isolated submandibular gland mumps
- Congenital absence of salivary glands in Down syndrome
- Salivary gland disease in dogs and cats
- Is injection of botulinum toxin type A effective in the treatment of drooling in children with cerebral palsy?